Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas - Wikidata - awgldk - TriplyDB

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

http://www.wikidata.org/entity/Q34236713

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Current challenges and novel treatment strategies in double hit lymphomas Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma.Role of MYC in B Cell Lymphomagenesis.Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies Genetic lesions in diffuse large B-cell lymphomas Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma.Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.From drug discovery to biomarker-driven clinical trials in lymphoma MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.A clinician's guide to double hit lymphomas.EBV-associated Burkitt lymphoma in Taiwan is not age-related.MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.Lymphoma classification update: B-cell non-Hodgkin lymphomas.High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects Epitope recognition in the human-pig comparison model on fixed and embedded material.Long-term survival in AIDS-related primary central nervous system lymphoma.The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.Double-Hit Large B Cell Lymphoma.MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection.

P2860

Q24597424-CCB0A687-3DCB-492B-B8D4-C61D6D4E90F6 Q26770385-D276A657-F236-45B9-8FAF-8FA8319A1DB6 Q27013785-7ABEF9ED-10EC-4BF0-9387-1F97E990A8B7 Q27304386-9D1AFE0B-1D86-4A43-A2E4-FAC3DF2BF748 Q30489244-CCA286F9-899D-4C51-9DE4-D1B7ABF4F279 Q33608499-AF97745F-8764-4399-80E6-67332643DE06 Q33700531-C31D61DE-B2AF-4454-B60B-9A5687A62DE4 Q33864145-6F580B25-B159-4C92-ADD0-D2FDFD22AC19 Q34000188-6CF5D7BB-EAB7-46BD-9A58-2001C9F83D1F Q34033206-1C8ADD5A-F644-4B85-B7A8-FD5FCFAA58D2 Q34371250-657218FF-DACA-479C-A0FE-AEEE3D24ECEB Q35150618-38AEDDDF-85DC-4D71-A88D-87999103FDD1 Q35974341-D7478A1C-8BFA-4DBF-B4F2-332F36030113 Q36093288-44E78001-8EB1-426B-BAEE-F913A645997E Q36267666-0876C7DF-564B-406C-BF30-27003CF61D9A Q36563205-23974B81-7C45-4DD0-86F5-AF29E1EEBA3A Q37042173-EF5D1229-298D-4C0C-B308-6283B153A9C9 Q37122287-10B1F784-B24C-428E-A112-5B0C615E3E44 Q37142412-E6889225-4E97-4A27-B85E-98F31F94D0D2 Q37212700-361E7401-0E1A-4C38-AE6C-F3A52BF40D03 Q37412155-7FE2FF1B-DB56-4E24-B481-80178FA7E0B1 Q37551148-72D6FFEF-6679-48DE-A001-DFF4DF7CD5C0 Q37617063-88535E67-4844-4FA1-831C-2E93DBBF5841 Q37640313-B9DFFB4C-21F0-4548-B115-290C2EC3CCF7 Q38179500-F05F595E-F485-4EC7-B9CB-B6D665D65D84 Q38233772-2E1DFBE5-C04C-4D03-91DD-46AD90F42B08 Q38296091-79CCA137-23E2-41BA-9878-C16D7D259FC0 Q38595746-420E9983-7669-4C39-B087-7F62D4BC1872 Q38719071-A4B1A727-9275-44F1-BC93-A5286B2E262B Q38843988-30CF2C4E-BE61-4264-845C-8BA1BFC6806D Q38975357-56B65894-E1CB-4E4B-9755-3A8F8C65E94B Q39221506-C9312127-CA1A-46CB-BBC8-AF056D474131 Q39943842-E7F01CA4-1161-4E1C-9342-36085D1186CE Q40557791-00343AD9-C0EF-40AD-A47E-FD6C35DF2817 Q40649778-2E2F522F-DCC3-4569-8161-A07D9ABF65AC Q40877769-F4B28B78-66D6-4FD8-82EE-EAD1ACFA500E Q43084886-4DBD4101-E89B-48FB-9FF7-9C3B5289BF49 Q43764468-5F277F76-60F0-45A1-B6B2-A5E48332E110 Q45304558-9DF2E451-D632-4751-8ED6-1DB11A448724 Q46017773-4A1EFCF0-6314-4154-B1A3-E30BEAE870D2

P2860

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

http://www.wikidata.org/entity/Q34236713

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@ast

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@en

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@nl

type

label

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@ast

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@en

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@nl

prefLabel

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@ast

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@en

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@nl

P1433

Q34236713-3A1A730F-DF1B-4802-B023-BB626FBE0AE6

P1476

Q34236713-78F07085-4EB1-4DA3-B531-FD832B83A6F2

P2093

Q34236713-109397E8-E4C8-46F6-A2B1-2076BDD5D2A6

Q34236713-2E88C4F7-D737-4872-91F2-D55E731FDF88

Q34236713-7B42538D-C1FA-44E9-88BF-36753E4C0E68

Q34236713-854046ED-AE2E-4B14-8CC0-BABB15A507AF

Q34236713-A5B43F01-B0B7-49BE-B607-EC079DF53FDD

Q34236713-E7660408-77C4-4CA6-ACFB-3CBA8298F913

Q34236713-FBAC8CED-57EA-4294-BD55-4A500A578931

Q34236713-FE233040-AD4C-40B4-8DD9-DC258467B8F0

Q34236713-FEC3854C-9735-43D4-AD92-5E0CDE8400EA

P2860

Q34236713-068A0449-AE69-4283-9BF6-54AC11F9700F

Q34236713-0857A316-9A84-4591-81F0-C6A35A9A4C5A

Q34236713-32D63F9B-E129-467D-90D8-A270D233AEE6

Q34236713-450C47F1-E66F-4877-B3A6-9A7C5A0B482C

Q34236713-46330804-350E-46A0-B1E4-2EAB8C13BFCB

Q34236713-5261AC7D-8311-47B9-AE96-8C68B0FA0C8A

Q34236713-80BE6E0B-FF97-4885-9FDF-DEF1AA7E461B

Q34236713-9516797E-476B-4335-8963-953A89EC9543

Q34236713-9BE9A292-153A-40B8-BAA7-82FDBA4E958A

Q34236713-9D0FD07C-D1CF-4A33-ADE7-C11BF028D1DD

P304

Q34236713-26F6C6B3-DDED-4EA8-ADA2-87F6E050A879

P31

Q34236713-EEDAD792-BC7A-49BE-BF2A-399FB00EF802

P356

Q34236713-465E6646-1131-424B-B699-A94A9115E911

P407

Q34236713-4F66D897-0590-4A6F-8526-46A1484E01DC

P433

Q34236713-19EDE916-69DB-4F18-B06F-BD3EE1284AC0

P478

Q34236713-A933051F-4BB8-4840-B579-1EF435990CD1

P50

Q34236713-BE5F679C-547F-4314-AD7C-28C42E00B1D7

P577

Q34236713-39CE9D9B-3669-4993-8898-53156DEFB690

P5875

Q34236713-79626F8F-1300-4D02-91E5-439B705EA072

P698

Q34236713-7533C18D-F086-4BAE-8394-202C6AB78DA4

P921

Q34236713-81D596E4-194D-4CE6-BDB4-F3F163AC041D

P932

Q34236713-9C0F5D51-0981-4E0E-9848-1AEA575BA236

P356

JOURNAL.PONE.0033813

P1433

P1476

Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas

@en

P2093

Alyssa Roy

http://www.w3.org/2001/XMLSchema#string

Bjoern Chapuy

http://www.w3.org/2001/XMLSchema#string

Donna S Neuberg

http://www.w3.org/2001/XMLSchema#string

Geraldine S Pinkus

http://www.w3.org/2001/XMLSchema#string

Margaret A Shipp

http://www.w3.org/2001/XMLSchema#string

Michael J Kluk

http://www.w3.org/2001/XMLSchema#string

Paola Dal Cin

http://www.w3.org/2001/XMLSchema#string

Papiya Sinha

http://www.w3.org/2001/XMLSchema#string

Scott J Rodig

http://www.w3.org/2001/XMLSchema#string

P2860

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Molecular biology of Burkitt's lymphoma.

Reflecting on 25 years with MYC.

Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment.

P304

e33813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0033813

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224285221

http://www.w3.org/2001/XMLSchema#string

P698

22511926

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3325231

http://www.w3.org/2001/XMLSchema#string